---
id: viral-hepatitis_108
category: organisms
tags: [hepatitis-A, hepatitis-B, hepatitis-C, DAA, entecavir, tenofovir]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Viral Hepatitis (HAV, HBV, HCV)

**Q:** What are the key features, serology interpretation, and treatment of hepatitis A, B, and C?

**A:**

## HEPATITIS A (HAV)

**Transmission:** Fecal-oral

**Clinical:** Acute hepatitis, jaundice, **NO chronic infection**

**Diagnosis:** **Anti-HAV IgM** (acute infection)

**Treatment:** **Supportive** (self-limited)

**Prevention:** **HAV vaccine** (2 doses)

---

## HEPATITIS B (HBV)

**Transmission:** Blood, sexual, perinatal

**Clinical:**
- **Acute:** 70% asymptomatic, 30% jaundice
- **Chronic:** 90% (infants), 5% (adults)

---

### **Serology Interpretation:**

| **HBsAg** | **Anti-HBs** | **Anti-HBc** | **HBeAg** | **Interpretation** |
|-----------|--------------|--------------|-----------|---------------------|
| **+** | - | IgM+ | +/- | **Acute HBV** |
| **+** | - | IgG+ | + | **Chronic HBV** (high replication) |
| **+** | - | IgG+ | - | **Chronic HBV** (low replication) |
| - | **+** | IgG+ | - | **Past infection** (immune) |
| - | **+** | - | - | **Vaccinated** |

**Key Point:** **HBsAg = active infection**, **Anti-HBs = immune**

---

### **Treatment (Chronic HBV):**

**Indications:** Elevated ALT + HBV DNA >2000 IU/mL

| **Agent** | **Dosing** | **Notes** |
|-----------|------------|-----------|
| **Entecavir** | **0.5-1 mg PO daily** | **Preferred** (high barrier to resistance) |
| **Tenofovir (TDF or TAF)** | **300 mg (TDF) OR 25 mg (TAF) PO daily** | **Preferred** |
| **Peginterferon alfa** | **180 Î¼g SC weekly x 48 weeks** | Finite duration, side effects |

**Key Point:** **Entecavir or tenofovir = first-line** (indefinite therapy)

**Complications:**
- **Cirrhosis** (20-30% chronic HBV)
- **Hepatocellular carcinoma** (HCC)

**Screening:** HCC surveillance (ultrasound + AFP every 6 months)

---

## HEPATITIS C (HCV)

**Transmission:** Blood (IVDU, transfusion pre-1992)

**Clinical:**
- **Acute:** 70-80% asymptomatic
- **Chronic:** 55-85% (no treatment)

**Complications:**
- **Cirrhosis** (10-20% over 20 years)
- **HCC**
- **Cryoglobulinemia, glomerulonephritis**

---

### **Diagnosis:**

**Screening:**
- **Anti-HCV antibody** (screening test)

**Confirmation (If Anti-HCV+):**
- **HCV RNA (PCR)** - confirms **active infection**
- **HCV genotype** (guides treatment - less important with newer DAAs)

**Key Point:** **Anti-HCV+ alone** does NOT distinguish active vs past infection (need HCV RNA)

---

### **Treatment:**

**Direct-Acting Antivirals (DAAs) - Curative:**

| **Regimen** | **Dosing** | **Duration** |
|-------------|------------|--------------|
| **Sofosbuvir/velpatasvir (Epclusa)** | **400/100 mg PO daily** | **12 weeks** (pan-genotypic) |
| **Glecaprevir/pibrentasvir (Mavyret)** | **3 tablets PO daily** | **8-16 weeks** (pan-genotypic) |
| **Ledipasvir/sofosbuvir (Harvoni)** | **90/400 mg PO daily** | **12 weeks** (genotype 1, 4, 5, 6) |

**Key Point:** **Pan-genotypic DAAs = cure >95%** (8-12 weeks)

**SVR (Sustained Virologic Response):**
- **HCV RNA undetectable 12 weeks post-treatment** = **cure**

**Key Point:** **SVR12 = cure** (>95% with DAAs)

---

## COMPARISON TABLE

| **Feature** | **HAV** | **HBV** | **HCV** |
|-------------|---------|---------|---------|
| **Transmission** | Fecal-oral | Blood, sexual, perinatal | Blood (IVDU) |
| **Chronic infection** | **NO** | **YES** (5% adults, 90% infants) | **YES** (55-85%) |
| **Diagnosis** | Anti-HAV IgM | **HBsAg** (active) | Anti-HCV + **HCV RNA** (active) |
| **Treatment** | Supportive | **Entecavir/Tenofovir** (indefinite) | **DAAs** (8-12 weeks, **CURATIVE**) |
| **Vaccine** | **YES** | **YES** | **NO** |

---

**Mnemonic: "HBsAg = Surface Antigen (Active Infection)"**
- **HBsAg+** = active HBV infection (acute or chronic)
- **Anti-HBs+** = immune (vaccinated or past infection)

**Mnemonic: "HCV DAAs = Cure (SVR12)"**
- **DAAs** = direct-acting antivirals
- **Cure >95%** (8-12 weeks)
- **SVR12** = undetectable HCV RNA at 12 weeks post-treatment

**Clinical Pearls:**
- **HAV = fecal-oral, NO chronic infection** (vaccine available)
- **HBsAg = active HBV** (acute or chronic)
- **Anti-HBs = immune** (vaccinated or past infection)
- **Entecavir/tenofovir = first-line for chronic HBV** (indefinite therapy)
- **HCV: Anti-HCV+ alone does NOT confirm active infection** (need HCV RNA)
- **DAAs cure HCV >95%** (8-12 weeks, pan-genotypic regimens)
- **SVR12 = cure** (HCV RNA undetectable 12 weeks post-treatment)

**Media:** None

**Sources:** [AASLD 2024 - HBV/HCV treatment guidelines]
